Valerio Therapeutics (XPAR:ALVIO) Total Liabilities : €20.47 Mil (As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

What is Valerio Therapeutics Total Liabilities?

Valerio Therapeutics's Total Liabilities for the quarter that ended in Dec. 2023 was €20.47 Mil.

Valerio Therapeutics's quarterly Total Liabilities increased from Dec. 2022 (€20.82 Mil) to Jun. 2023 (€20.85 Mil) but then declined from Jun. 2023 (€20.85 Mil) to Dec. 2023 (€20.47 Mil).

Valerio Therapeutics's annual Total Liabilities increased from Dec. 2021 (€20.12 Mil) to Dec. 2022 (€20.82 Mil) but then declined from Dec. 2022 (€20.82 Mil) to Dec. 2023 (€20.47 Mil).

Valerio Therapeutics Total Liabilities Historical Data

The historical data trend for Valerio Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Valerio Therapeutics Total Liabilities Chart

Valerio Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

20.43

17.47

20.12

20.82

20.47

Valerio Therapeutics Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Liabilities	Get a 7-Day Free Trial															20.12	26.81	20.82	20.85	20.47

Valerio Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Valerio Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	11.13	+	(7.219	+	2.12
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	20.47

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	35.274	-	14.805
	=	20.47

Valerio Therapeutics's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	11.13	+	(7.219	+	2.12
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	20.47

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	35.274	-	14.805
	=	20.47

Valerio Therapeutics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Valerio Therapeutics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Valerio Therapeutics (XPAR:ALVIO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Valerio Therapeutics (XPAR:ALVIO) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

C4X:Germany

Address

49 Boulevard du General, Martial Valin, Paris, FRA, 75015

Website

https://www.valeriotx.com

Valerio Therapeutics is a clinical-stage biotechnology company designing and developing novel oncology drugs targeting tumor DNA repair functions. Its therapeutic strategy focuses on fighting tumor resistance to treatments, which poses ever-greater therapeutic challenges, especially in aggressive or rare cancers. its approach is based upon unique mechanisms of action on DNA Damage Response. The company focuses on bringing first-in-class and disruptive compounds from preclinical research to proof-of-concept in man in cancer indications with high unmet needs.

Valerio Therapeutics (XPAR:ALVIO) Headlines

No Headlines